- Pharmaceutics International Inc. (Pii) launches Accelevate, a platform to help small and mid-sized pharmaceutical companies achieve IND readiness in 100 days.
- The platform integrates advanced technology and regulatory expertise to streamline development and submission processes for aseptic products.
Pharmaceutics International Inc. (Pii) has launched the Accelevate Early Development Platform, aiming to help small and mid-sized pharmaceutical companies accelerate their path to Investigational New Drug (IND) readiness in just 100 days. This platform targets aseptic products and supports companies that may lack the internal resources to navigate early-stage development.
The platform’s primary goal is to reduce time-to-market pressure in the pharmaceutical industry, especially for smaller companies. By leveraging advanced technology, regulatory expertise, and dedicated project management, Accelevate provides a streamlined approach from molecule identification to IND submission.
Accelevate employs in silico modeling and machine learning to expedite the development process while maintaining strict adherence to FDA, EMA, and ICH guidelines. In addition to ensuring rapid data generation, the platform supports pre-clinical studies, safety assessments, and regulatory document preparation. Clients are supported by Pii’s project management team, which ensures critical development milestones are met within the 100-day timeframe.
Commenting on the platform, Travis Webb, Chief Scientific Officer of Pii, said, “Accelevate represents a significant advancement for smaller pharmaceutical companies, enabling them to move through the early development process with unprecedented speed. We are empowering these companies to remain competitive in a fast-paced market by reducing the timeline for IND submission without compromising on regulatory compliance.”
Overview of outsourcing trends 
